GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IXICO PLC (LSE:IXI) » Definitions » Price-to-Owner-Earnings

IXICO (LSE:IXI) Price-to-Owner-Earnings : (As of Apr. 27, 2024)


View and export this data going back to 1996. Start your Free Trial

What is IXICO Price-to-Owner-Earnings?

As of today (2024-04-27), IXICO's share price is £0.08625. IXICO does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for IXICO's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of IXICO was 48.96. The lowest was 27.08. And the median was 37.08.


LSE:IXI's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 31.62
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-04-27), IXICO's share price is £0.08625. IXICO's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was £-0.02. Therefore, IXICO's PE Ratio for today is At Loss.

As of today (2024-04-27), IXICO's share price is £0.08625. IXICO's EPS without NRI for the trailing twelve months (TTM) ended in was £-0.02. Therefore, IXICO's PE Ratio without NRI for today is At Loss.

During the past 13 years, IXICO's highest PE Ratio without NRI was 102.78. The lowest was 0.00. And the median was 29.14.


IXICO Price-to-Owner-Earnings Historical Data

The historical data trend for IXICO's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IXICO Price-to-Owner-Earnings Chart

IXICO Annual Data
Trend Sep13 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 40.42 - - -

IXICO Semi-Annual Data
Sep13 Mar14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of IXICO's Price-to-Owner-Earnings

For the Biotechnology subindustry, IXICO's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IXICO's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IXICO's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where IXICO's Price-to-Owner-Earnings falls into.



IXICO Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

IXICO's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.08625/-0.03
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IXICO  (LSE:IXI) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


IXICO Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of IXICO's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


IXICO (LSE:IXI) Business Description

Industry
Traded in Other Exchanges
Address
15 Long Lane, 4th Floor, Griffin Court, London, GBR, EC1A 9PN
IXICO PLC is a UK-based company engaged in providing clinical trial services and technology to evaluate imaging endpoints to pharmaceutical companies. Its therapeutic areas include Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis, Progressive Supranuclear Palsy, and Other Rare Neurological Diseases. Services offered by the company are Early Phase Clinical Development, Late Phase Clinical Development, Post-Marketing, and Consultancy. The company's geographical segments include the United States, Switzerland, the United Kingdom, the Netherlands, Ireland and other- Europe. The Company work with healthcare organizations across the entire clinical research journey, for drug development analytics, medical imaging operations and post-marketing surveillance.

IXICO (LSE:IXI) Headlines

No Headlines